PCN65 A COST-EFFECTIVENESS ANALYSIS OF THE FIRST-LINE TREATMENT REGIMENS FOR MULTIPLE MYELOMA IN MACAO CHINA

s A35 gained. RESULTS: Patients were categorized into 5FU/LV (n = 2,834), oxaliplatin based (n = 621), and irinotecan based (n = 945) subgroups, based on the regimen they received. The median improvement in overall survival with 5FU/LV, irinotecan or oxaliplatin based combination therapy was 1.25, 1.34, and 1.72 life-years, respectively. The incremental cost with irinotecan or oxaliplatin based combination therapy compared with 5FU/LV was $205,837 and $93,651, respectively. When comparing to irinotecan based combination therapy, the incremental cost-effectiveness ratio of oxaliplatin based combination therapy was $67,637 per life-year gained. CONCLUSIONS: This analysis suggests that oxaliplatin or irinotecan based combination therapy improves overall survival but also substantially increases direct medical costs compared with 5FU/LV when used in elderly US patients with stage IV colon cancer. Oxaliplatin-based regimens are more cost-effective than irinotecan based regimens. PCN61 THE COST-EFFECTIVENESS OF CETUXIMAB USE AMONG ELDERLY METASTATIC COLORECTAL CANCER PATIENTS